Redaktion

**Hoffnung für seltene Psoriasis-Form** Eine seltene und schwere Psoriasis-Form lässt sich besser behandeln als bisher gedacht. Forscher aus Bayern untersuchten 29 Patienten. Die meisten erhielten biologische Medikamente. Bei allen Patienten verbesserte sich die Erkrankung deutlich. Die Messwerte der Schwere sanken stark. Besonders wirksam sind Medikamente gegen die Botenstoffe IL-17 und IL-23. Einige Patienten wurden sogar ganz gesund. Ältere Medikamente verursachten mehr Nebenwirkungen. Ärzte fordern nun klare Behandlungsrichtlinien. Originaltitel: Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study. Link zur Quelle

Biosimilars demonstrate **comparable efficacy and safety to originator biologics** for moderate-to-severe psoriasis while offering substantially lower costs, creating significant potential to expand treatment access in low- and middle-income countries where price barriers currently restrict patients' access to effective treatments.[1][2][5] **Clinical Equivalence Confirmed** A systematic review of 14 randomized clinical trials and 3 cohort studies found no clinically or statistically significant differences in efficacy and safety between biosimilars and their originator products for psoriasis treatment.[5] Specific comparisons—including biosimilar MSB11022 (adalimumab) and CT-P13 (infliximab)—showed similar reductions in Psoriasis Area and Severity Index scores and comparable adverse event rates.[1] Twenty-four biosimilars derived from 4 reference products are now approved for psoriasis treatment in the United States.[6] **Addressing Access Barriers** Although biologic therapies have significantly improved psoriasis outcomes, their high costs have limited access and created healthcare inequalities, particularly in resource-limited regions.[2] Biosimilars promise to improve patient access to these proven effective treatments while maintaining improved health outcomes and reducing overall treatment costs.[2] **Important Considerations and Limitations** Evidence quality varies across settings. Most clinical evidence derives from randomized controlled trials; high-quality real-world effectiveness data across diverse healthcare systems remains limited.[5] Biosimilars can receive regulatory approval for psoriasis based on extrapolated evidence from other diseases rather than direct psoriasis trials.[5] Long-term safety and immunogenicity data are limited compared to originators due to their shorter market presence.[1] Additionally, patent protections continue to restrict biosimilar availability in some regions.[3] While switching from originator to biosimilar appears safe based on available evidence, careful patient monitoring during transitions remains important.[2] Originaltitel: The role of biosimilars in enhancing global access to psoriasis treatment Link zur Quelle

I notice that while your query references a specific cross-sectional survey on patient attitudes toward digital health interventions in dermatology, the full study details aren't included in the search results provided. However, I can share what the search results reveal about **dermatological patients' attitudes toward digital health interventions**: ## Patient Acceptance and Interest Patients generally show **positive attitudes and interest in digital health tools**, though their actual adoption remains limited[1]. Only a small minority of patients (6%) had prior experience with digital health interventions before participating in studies[1]. Importantly, patients reported being **dependent on their dermatologists' acceptance** of these tools—meaning they're more likely to use digital solutions if their physicians recommend them[1]. ## Key Barriers and Facilitators The main obstacle is **lack of digital competence**: inadequate digital health literacy affects a significant portion of patients, ranging from 22% in Norway to 58% in Germany[1]. Additionally, patients exhibit **hesitancy toward AI-based diagnoses without dermatologist involvement**—84% of patients prefer a dermatologist's diagnosis over AI alone[4]. Trust remains crucial: patients strongly prefer receiving dermatology information directly from their dermatologists (99%), with 78% reporting high satisfaction with physician-provided information[5]. ## Practical Implications For these findings to translate into better care, digital health tools must be **user-friendly and adapted to varying skill levels**[1]. Data privacy transparency is essential, and successful implementation requires dermatologists' active endorsement and integration into existing workflows[1]. To provide more detailed analysis of the specific study you're referencing, please share the complete study text or clarify which results you'd like me to focus on. Originaltitel: Attitudes of dermatological patients towards digital health interventions: a cross‐sectional survey and cluster analysis Link zur Quelle

**Spurenelemente und deine Gelenkschmerzen** Forscher haben etwas Neues herausgefunden. Menschen mit Psoriasis-Arthritis haben oft zu wenig von bestimmten Stoffen im Blut. Diese Stoffe heißen Spurenelemente. Die wichtigsten sind Selen, Kupfer und Zink. Dein Körper braucht sie wirklich. Eine neue Studie hat 160 Patienten untersucht.[1] Die Forscher verglichen Menschen mit Psoriasis-Arthritis mit gesunden Menschen. Das Ergebnis war eindeutig. Allen Patienten fehlten diese wichtigen Spurenelemente. Das Interessante: Wenn die Entzündungswerte steigen, sinken die Selen-Werte besonders.[1] Das ist kein Zufall. Vielleicht könnte Selen-Behandlung dir helfen. Sie könnte deine Entzündung besser kontrollieren. Die gute Nachricht: Ärzte wissen das jetzt. Bald könnten personalisierte Behandlungen mit diesen Stoffen dir Erleichterung bringen.[1] Sprich mit deinem Arzt darüber. Originaltitel: Trace Element Deficiency in Axial Spondyloarthritis and Psoriatic Arthritis in Relation to Markers of Inflammation and Remission. Link zur Quelle

Psoriasis is a relapsing autoimmune disease exacerbated by aberrant interleukin (IL)-17 A activity. Majoon Ushba, a unani polyherbal formulation implicated in clinical cases of psoriasis lacks immunopharmacological validation. The study aims to investigate the pre-clinical efficacy of Majoon Ushba and its therapeutic role in mitigating IL-17A-induced keratinocytes ferroptosis via ablation of JAK-2/STAT-3 pathway. HaCaT cells were stimulated with IL-17A to assess the activation of the JAK-2-STAT-3 pathway. The STAT-3 inhibitor, S3I-201, was used to confirm the role of the STAT-3 axis in keratinocyte ferroptosis. Majoon Ushba pretreatment was assessed to determine its efficacy in alleviating keratinocyte ferroptosis. An imiquimod (IMQ)-induced psoriasis mouse model was used to evaluate the pre-clinical efficacy of Majoon Ushba. Furthermore, prior high-performance liquid chromatography (HPLC) profiling was leveraged for in-silico docking analysis to identify the binding affinities of key phytoconstituents with IL-17RA and STAT-3. Majoon Ushba alleviated the IL-17A/JAK-2-STAT-3 axis, improved GPX4 expression, and regulated lipid peroxidation. Subsequently, Majoon Ushba also reversed the expression of pathogenic mediators and led to a reduction in serum cytokine levels of IL-17A, IL-23, and IFN-γ. An in-silico docking analysis suggested favorable binding affinities for key phytoconstituents of Majoon Ushba against IL-17RA and STAT-3. Aligned with pre-clinical and in vitro results, the computational findings offer initial evidence that the polyherbal formulation may influence the IL-17A/JAK-2-STAT-3 signaling pathway. In conclusion, our preliminary findings reveal a plausible mechanistic basis for the anti-psoriatic efficacy of Majoon Ushba, warranting larger clinical trials in psoriasis patient cohorts.Weiterlesen

To compare the efficacy and safety of different ustekinumab biosimilars for treating moderate-to-severe plaque psoriasis (PP), providing an evidence-based basis for clinical medication. We systematically searched randomized controlled trials on ustekinumab biosimilars for treating moderate-to-severe PP in adults from Embase, PubMed, Cochrane Library, and Web of Science. Stata 18.0 was utilized for data analysis. Nine studies were included, involving 4293 moderate-to-severe PP patients. 1) Ustekinumab biosimilars and the reference listed drug (RLD) ustekinumab-RP had no significant difference in the psoriasis area and severity index (PASI) improvement (P > 0.05), and the biosimilar CT-P43 was most effective in improving PASI at different time points. 2) For the dermatology life quality index, Bmab1200, AVT04 and CT-P43, had statistically significant differences from the RLD (P < 0.05). 3) The biosimilar CT-P43 was most effective in improving the Physician Global Assessment score, with the highest SUCRA value (99.8%). 4) The reduction of the body surface area and the treatment-emergent adverse event rate had no statistically significant difference from the RLD (P > 0.05). 5) The biosimilar CT-P43 and Bmab1200 demonstrated a lower probability of generating anti-drug antibodies, showing statistically significant differences from other biosimilars (P < 0.05). Ustekinumab biosimilars demonstrate comparable efficacy and safety to ustekinumab-RP for treating moderate-to-severe PP in adults. The biosimilar CT-P43 is more effective in improving short-term PASI. Due to limitations in the number and quality of included studies, more high-quality studies are required to validate these findings.Weiterlesen

IntroductionThis study analyzed the mechanisms of action of Andrographis paniculata (AP), a medicinal plant with diverse pharmacological properties, on psoriasis.Materials and methodsThe active components of AP and their corresponding targets were identified. These targets were subsequently intersected with differentially expressed genes (DEGs) and immune-related genes associated with psoriasis. The resulting gene set was subjected to functional enrichment analysis and immune infiltration analysis. The scRNA-seq data were analyzed to delineate the single-cell landscape in psoriasis and cell type-specific expression of genes of interest. Further, the molecular docking and experimental verification were performed for validation.ResultsActive components of AP and their targets were predicted. Cross-referencing these targets with psoriasis DEGs revealed 2 feature genes (AR and ITGAL), both exhibiting strong diagnostic potential. The two genes were associated with differentially enriched pathways and immune cell infiltration. Further, scRNA-seq analysis identified 10 cell subclusters. Notably, AR was expressed in reticular fibroblasts of healthy controls, while ITGAL was expressed in T cells of psoriasis samples. Molecular docking confirmed a stable binding interaction between Dehydroandrographolide and AR. In vitro validation using an M5 cytokine-induced keratinocyte model demonstrated that Dehydroandrographolide exerted potent anti-inflammatory and antiproliferative effects. Furthermore, it significantly modulated the protein expression levels of both genes.DiscussionCombining in-silico and in-vitro analyses, this study identified AR and ITGAL as potential key mediators and validated the efficacy of the active component of AP, Dehydroandrographolide, against psoriasis.ConclusionCollectively, the study demonstrated that AP had the potential anti-psoriasis effects.Weiterlesen

BackgroundPsoriasis is a chronic, immune-mediated skin disorder that causes physical, psychological, and social burdens. There is a growing need to better characterize the distinct clinical features and specific treatment needs of elderly patients with psoriasis, which remains an important area for further research to optimize care in this population.ObjectiveTo investigate the clinical characteristics, comorbidities, and treatment preferences of elderly patients with psoriasis vulgaris.MethodsPatients with psoriasis vulgaris were included in this retrospective study. Data on demographics, disease characteristics, including age at diagnosis, body surface area (BSA), Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), comorbidities, and treatment needs were collected. Patients at the visit over 60 years of age were defined as elderly patients. Patients who were diagnosed before 40 years of age were defined as early-onset psoriasis (EOP), and patients who were diagnosed over 40 years of age were defined as late-onset psoriasis (LOP). Continuous variables were compared using t-tests or Mann-Whitney U-tests, categorical variables using Chi-square or Fisher's exact tests. Spearman correlation was used for association analysis. Statistical significance was set at P<0.05.ResultsA total of 375 patients were included, comprising 70 (18.67%) elderly and 305 (81.33%) non-elderly patients. The elderly group had a significantly higher proportion of LOP (87.14% vs 48.76%, P<0.05). A higher percentage of elderly patients had moderate-to-severe (27.14% vs 20.98%, P<0.05) and severe (1.43% vs 0.66%, P<0.05) disease. Comorbidities were more prevalent in the elderly, including cardiovascular disease (12.86% vs 3.93%, P<0.05) and diabetes (12.86% vs. 1.31%, P<0.05). Despite this, elderly patients reported lower DLQI scores (median 2.00 vs. 3.00, P<0.05). Regarding treatment needs, elderly patients were less likely to prioritize reducing treatment costs (10.00% vs 20.98%, P<0.05) and preventing disease recurrence (30.00% vs 44.26%, P<0.05) compared to non-elderly patients. Within the elderly cohort, EOP patients exhibited more severe disease (median BSA: 3.00 vs 2.00; median PASI: 3.30 vs 0.80, P<0.05), a higher rate of familial psoriasis (33.33% vs 4.92%, P<0.05), and a greater demand for reducing treatment costs (33.3% vs 6.56%, P<0.05) compared to LOP patients.ConclusionElderly patients with psoriasis present a distinct clinical profile characterized by a high prevalence of late-onset disease, a significant comorbidity burden, and differing treatment priorities focused less on cost and recurrence. Despite the increased clinical severity, their perceived quality-of-life impact is lower. Besides, they report higher dissatisfaction linked to unmet needs in itch relief, drug safety, and long-term control. Within the elderly cohort, early-onset patients had more severe disease, stronger familial predisposition, and greater cost-related concerns. The findings highlight the necessity for age-specific, multidimensional management strategies for this population.Weiterlesen

BackgroundLifestyle factors have the potential to enhance well-being and quality of life (QoL). This study aimed to identify lifestyle patterns among UK-based adults with psoriasis and examine associations with QoL.MethodsThis was a cross-sectional analysis of the 'Asking People with Psoriasis about Lifestyle and Eating' (APPLE) study (n=353). QoL, Body Mass Index (BMI), and physical activity were assessed using the Dermatology Life Quality Index (DLQI), self-reported weight and height, and the International Physical Activity Questionnaire.ResultsParticipant demography was: 82% female; mean (SD) age of 41 (13) years; and BMI of 27 (7) kg/m2. When fully adjusted for age, sex, smoking, and alcohol use, compared to individuals in the highest BMI tertile (35 (5) kg/m2), those in the lowest tertile (21 (2) kg/m2) reported a 71% reduced likelihood of QoL impairments (Odds Ratio (OR) = 0.29; 95% CI 0.14-0.59, adjusted P<0.01). Dairy-free, gluten-free, and pescatarian diets were more frequently adopted in individuals reporting healthy BMIs (≈24 kg/m2, adjusted P<0.05). Higher levels of physical activity (2932 (1509) Metabolic Equivalent of Task Minutes per week), and adequate sleep duration (7 (0) hours/day) were associated with lower odds of QoL impairments, although attenuated by multiple testing. Participants affected by embarrassment or self-consciousness related to their psoriasis engaged in less vigorous-intensity and walking activities compared to those who were less affected (adjusted P<0.05).ConclusionsAssessing weight status and physical activity in individuals reporting high DLQI scores may help identify modifiable behaviours contributing to poorer QoL and thereby shape interventions.Weiterlesen

This study collected and analyzed clinical data of psoriasis patients to develop and validate a psoriasis relapse risk prediction model. It aims to support early relapse risk assessment in clinical practice and inform the design of preventive interventions. To develop and validate a risk prediction model for psoriasis relapse. A convenience sampling method was used to select 504 psoriasis patients admitted to a tertiary hospital in China between January 2022 and December 2024, including 353 cases in the training set and 151 cases in the testing set. Independent risk factors for psoriasis relapse were identified through univariate analysis and logistic regression analysis to develop a prediction model. A nomogram and SHAP summary plot were generated for model visualization, and the model's goodness of fit and discriminative ability were evaluated. The 1-year relapse rate of psoriasis patients after treatment was 66.67%. Logistic regression identified six independent risk factors for psoriasis relapse: BMI, diabetes, biologic use, smoking, upper respiratory tract infection (URTI), and non-standard medication, all of which were incorporated into the model. The area under the ROC curve (AUC) values for the training and testing sets were 0.767 [95% CI 0.715-0.818] and 0.704 [95% CI 0.620-0.789], respectively. The model showed moderate discrimination and good calibration. Decision curve analysis (DCA) confirmed clinically meaningful net benefit in both training and test sets. The predictive model for psoriasis relapse risk established in this study demonstrated only moderate predictive performance. This model can serve as a preliminary exploratory tool, providing a certain degree of quantitative reference for assessing the risk of psoriasis relapse; however, rigorous external validation in independent multicenter cohorts is still required before clinical application.Weiterlesen

ObjectivesThere is very limited data regarding atlantoaxial instability (AAI) in patients with psoriatic arthritis (axPsA). In this study, we aimed to contribute to the existing literature on this topic.MethodsAdult patients were included in this single-center study who were classified as PsA by the 'CASPAR' criteria and evaluated as having axial involvement according to the 'Calin' criteria. Those with inflammatory or non-inflammatory diseases that could affect the spine were excluded. Electronic patient files were reviewed retrospectively. Lateral neutral/full extension/full flexion and open-mouth anteroposterior cervical radiographs were evaluated by three rheumatologists blinded to the patients. Patients were compared in two groups as AAI-positive and AAI-negative.ResultsA total of 100 patients with a mean age of 48.8 years and a mean PsA duration of 7.4 years, 57% of whom were female, were included in the study. A total of 20 AAI lesions were detected in 18% patients; subaxial subluxation was detected in eight, anterior atlantoaxial subluxation (AAS) in seven, posterior AAS in three, lateral AAS in one, and vertical subluxation in one case. In the group with AAI, the presence of psoriasis (Ps) (p = 0.037), scalp psoriasis (p < 0.001), and the use of targeted therapy for Ps and PsA (p < 0.001, p < 0.001) were significantly higher than in the AAI-negative group.ConclusionGiven that Ps and PsA patients on targeted therapy may reflect cases with higher disease activity and inadequate response to conventional treatments, it may be appropriate to consider closer monitoring for AAI in these patients. Key Points • Atlantoaxial instability is present in approximately one-fifth of patients with axial psoriatic arthritis. • The most common instability lesion is subaxial subluxation, accounting for 40% of all lesions. • The presence of psoriasis, scalp psoriasis, and the use of targeted therapies for psoriatic arthritis or psoriasis are significantly more frequent in the group with atlantoaxial instability. These factors may be useful for cervical spine monitoring in patients with axial psoriatic arthritis. • The use of targeted therapies for psoriatic arthritis or psoriasis may indirectly indicate an association between high disease activity and atlantoaxial instability.Weiterlesen

Originaltitel: Difficult to treat disease in psoriatic arthritis- is it different from axial spondyloarthritis? Link zur Quelle

Originaltitel: Using causal machine learning and real world data to improve dose response decision making for secukinumab in psoriatic arthritis. Link zur Quelle

# Psoriasis arthritis verbindet Haut- und Gelenkerkrankung Wissenschaftler haben eine spannende Entdeckung gemacht. Sie zeigt, dass Psoriasis arthritis wie eine Brücke zwischen zwei Krankheiten funktioniert. Auf der einen Seite steht die Gelenkerkrankung Rheumatoide Arthritis. Auf der anderen Seite steht die Hauterkrankung Psoriasis. Die Forscher untersuchten spezielle Blutzellen namens Monozyten. Sie schauten sich an, wie diese Zellen bei Psoriasis arthritis arbeiten. Dabei fanden sie etwas Besonderes. Psoriasis arthritis hat nämlich Merkmale von beiden Krankheiten gleichzeitig. Die Wissenschaftler entdeckten auch gemeinsame Entzündungsmuster. Diese treten bei allen drei Erkrankungen auf. Besonders interessant ist: Bei Psoriasis arthritis wirken zwei verschiedene Entzündungsprogramme gleichzeitig. Das eine wirkt wie bei der Gelenkerkrankung. Das andere wirkt wie bei der Hauterkrankung. Was bedeutet das für dich? Diese neuen Erkenntnisse helfen Ärzten besser zu verstehen, was in deinem Körper passiert. Sie könnten künftig auch bessere Vorhersagen machen. Das bedeutet: Deine Behandlung könnte später noch gezielter auf dich abgestimmt werden. Originaltitel: Psoriatic arthritis monocyte DNA methylomes bridge joint and skin inflammatory pathways across rheumatoid arthritis and psoriasis. Link zur Quelle

# Neue Daten zeigen: So häufig ist Psoriasis wirklich Forscher haben untersucht, wie oft Psoriasis und andere Erkrankungen bei Menschen ab 50 Jahren in Deutschland auftreten. Dafür nutzen sie Daten von Millionen versicherten Personen. Das Ergebnis ist interessant für Menschen mit Psoriasis. Bei Männern ab 50 treten pro 100.000 Menschen zwischen 268 und 430 Fälle von Psoriasis auf. Bei Frauen sind es 230 bis 412 Fälle. Das bedeutet: Männer erkranken etwas häufiger an Psoriasis als Frauen. Die genaue Häufigkeit hängt vom Alter ab. Die Forscher wollten vor allem herausfinden, welche Nebenwirkungen nach einer Impfung normal sind. Deshalb brauchten sie diese genauen Zahlen. Sie zeigen, wie oft Psoriasis und ähnliche Erkrankungen ohne Impfung auftreten würden. Die Studie nutzte echte Krankenkassendaten. Das macht die Ergebnisse sehr zuverlässig. Ärzte können diese Werte jetzt besser einschätzen, ob eine Erkrankung durch eine Impfung verursacht wurde. Für Patienten bedeutet das: Es wird sicherer nachvollziehbar, ob eine Impfung wirklich schuld an einer neuen Diagnose war. Originaltitel: Sex- and age-specific background incidence rates for various medical events in the German population aged ≥ 50 years using a nationwide monitoring system of claims data. Link zur Quelle